Emcure Doubling Down on Biosimilars Pipeline: MD Satish Mehta

Why It Matters

By leveraging patent cliffs and partnership models, Emcure can accelerate revenue growth and increase affordable biologic access in price‑sensitive markets, strengthening its competitive position in the fast‑growing biosimilars arena.

Key Takeaways

• Emcure has six biosimilars on market via Gennova subsidiary
• Company will seek external partners for biosimilar commercialization in India
• Generic semaglutide launch planned for second wave as patents expire
• Strategy targets emerging markets amid global biosimilar demand surge

Pulse Analysis

The worldwide biosimilar sector is entering a period of rapid expansion as a wave of biologic patents expires across the United States, Europe and Asia. Analysts project that global biosimilar sales could exceed $70 billion by 2030, driven by cost‑pressured health systems and rising demand for treatments such as insulin, oncology antibodies and GLP‑1 agonists. Emerging economies are especially attractive because they combine large patient populations with limited access to originator biologics. This macro‑trend creates a fertile environment for companies that can quickly bring affordable copies to market.

Emcure Pharmaceuticals, through its Gennova Biopharmaceuticals arm, already commercializes six biosimilars in India, all developed internally. The firm now intends to broaden its portfolio by partnering with external developers to acquire products that are not in its current pipeline, targeting both domestic distribution and export to other emerging markets. A flagship move is the planned launch of a generic version of semaglutide, the GLP‑1 drug best known under the brand Ozempic, whose patent protection lapses in several regions this year. Emcure expects this to be part of a second‑wave rollout after the initial market entry.

The strategy could boost Emcure’s top line by tapping into the high‑margin segment of diabetes and obesity therapies, while also diversifying revenue away from its existing oncology and cardiovascular biosimilars. By leveraging partnerships, the company reduces R&D risk and accelerates time‑to‑market, a critical advantage in a competitive landscape that includes global players such as Samsung Bioepis and Sandoz. For Indian patients, a lower‑cost semaglutide could improve treatment adherence and alleviate pressure on public health budgets. However, success will depend on regulatory approvals, pricing negotiations, and the ability to scale manufacturing for biologics at commercial volumes.